Fast Tracked Reviews and Complaints Fast Tracked carries specific operational specifications sponsors should know about, and when you unpack those details you see why the process is accessible but still rigorous; for example, the request for Fast Tracked designation can be submitted concurrently with an Investigational New Drug application or at any time after IND submission, and while the ideal timing is ahead of the pre-NDA meeting sponsors often request Fast Tracked earlier to secure guidance during pivotal study design, which is allowed under the Fast Tracked rules because the FDA recognizes that early collaboration can yield better outcomes. Fast Tracked eligibility is defined by two criteria: the drug must be intended to treat a serious condition and it must demonstrate potential to address an unmet medical need, and the Fast Tracked definition of 'serious condition' covers diseases that substantially impact daily functioning or reduce life expectancy—examples under the Fast Tracked umbrella include AIDS, Alzheimer's, many cancers, heart failure, epilepsy, severe depression, and diabetes complications—so sponsors seeking Fast Tracked status should map their clinical program to those disease characteristics when preparing their Fast Tracked request. Fast Tracked comes with procedural timing: the FDA aims to make a decision on Fast Tracked requests within 60 days, and if Fast Tracked is granted sponsors should expect ongoing engagement via meetings and written feedback throughout development; conversely, the FDA can remove Fast Tracked status if new information shows the product no longer meets the criteria, which keeps Fast Tracked focused and conditional on continued demonstration of unmet need and seriousness of the condition.
Fast Tracked Reviews and Complaints Fast Tracked is the name I use here to refer to the FDA's Fast Track designation, and when I say Fast Tracked I mean the formal regulatory status granted by the U.S. Fast Tracked as a concept is administered by the FDA and was created to shorten the time between promising research and patient availability, and when a company is Fast Tracked it gains privileges like more frequent meetings and written communications with regulators, the ability to submit portions of its application on a rolling basis, and eligibility to be considered for related pathways such as Accelerated Approval or Priority Review; Fast Tracked therefore operates across the lifecycle of drug development, from pre-IND interactions through pre-NDA or pre-BLA discussions, and sponsors that secure Fast Tracked status can use that status to clarify trial design, biomarker use, and the evidence needed to demonstrate benefit without changing the safety standards for approval. Order Now Fast Tracked USA